TLDR
- First quarter adjusted EPS reached $0.75, surpassing Wall Street’s $0.72 consensus estimate
- Quarterly revenue totaled $13.8 billion, driven by robust Eliquis blood thinner sales
- Net income declined 9% annually to $2.7 billion; diluted earnings per share fell 10%
- 2026 full-year projections maintained: adjusted EPS of $2.80–$3.00, revenue of $59.5B–$62.5B
- Shares advanced roughly 0.5% in premarket activity to about $26.33
Pfizer launched 2026 on solid footing with a first quarter earnings performance that exceeded expectations, pushing shares up approximately 0.5% to $26.33 during premarket hours.
The pharmaceutical giant delivered adjusted earnings of $0.75 per share, topping the analyst consensus of $0.72. Quarterly revenue reached $13.8 billion.
The company’s anticoagulant medication Eliquis, among its most lucrative products, maintained strong momentum. This drug continues serving as a critical pillar while legacy medications demonstrate surprising resilience.
Chief Financial Officer David Denton highlighted 22% operational revenue expansion from newly introduced and acquired therapies. This metric represents a foundation Pfizer aims to strengthen moving forward.
Net profitability experienced a downturn, though. The pharmaceutical manufacturer recorded $2.7 billion in net income, representing a 9% decrease compared to the prior year period. Diluted earnings per share settled at $0.47, marking a 10% year-over-year reduction.
Annual Projections Remain Intact
Pfizer stood by its 2026 financial outlook, preserving the guidance initially disclosed in December. Management continues to anticipate adjusted EPS ranging from $2.80 to $3.00 alongside full-year revenue between $59.5 billion and $62.5 billion.
Wall Street analysts had projected $2.96 per share alongside $61.4 billion in revenue, both figures falling comfortably within Pfizer’s guidance corridor.
The company additionally confirmed no share repurchase program is anticipated for 2026. This stance remains unchanged irrespective of performance throughout the year.
Chief Executive Albert Bourla adopted an optimistic stance. “We’re off to a strong start in 2026,” he stated, highlighting favorable Phase 3 clinical outcomes and promising mid-stage trial data.
Bourla emphasized oncology and obesity therapeutics as two sectors where he anticipates Pfizer is “positioned to lead.”
Patent Expiration Concerns Persist
Looming patent expirations represent one of Pfizer’s most significant immediate hurdles. Critical intellectual property protections covering blockbuster medications, including Eliquis, are scheduled to lapse before 2030.
Pfizer has implemented strategies to mitigate this impact. Management has negotiated arrangements with generic drug producers to prolong exclusivity periods for select products, including Vyndaqel.
The organization has simultaneously expanded its portfolio through strategic acquisitions and internal development initiatives to strengthen its product pipeline.
Management characterized the R&D pipeline as progressing across numerous therapeutic areas, with oncology and obesity results capturing significant leadership focus.
First quarter revenue expanded 5% year-over-year to $14.5 billion on a reported basis, exceeding market projections entering the earnings release.
The combination of earnings and revenue beats delivered investors a more favorable quarter than widespread expectations had suggested.
